s
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
13-06-2024, 17:03
SAINT-CLOUD, France, June 13, 2024 /PRNewswire/ — Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical. Leader in essential medicines for central nervous system, hospital care and internal medicine, Ethypharm’s strategy is to continue to grow […] L'articolo Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China proviene da La Ragione.
CONTINUA A LEGGERE
3
0
0
Guarda anche
Libero Quotidiano
![Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China](/img/static/get.php?image=https://www.liberoquotidiano.it/assets/images/placeholder_libero_gallery.png)
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
Libero Quotidiano
![Bluecrux Expands Global Presence with Barcelona Office](/img/static/get.php?image=https://www.liberoquotidiano.it/assets/images/placeholder_libero_gallery.png)